Importantly, mice that underwent complete IL-13Rα2-positive tumor regression were also protected against rechallenge with IL-13Rα2-negative tumors, suggesting that the IL-13Rα2-specific CARs assist in the development of diversified long-term anti-glioma immunity (76). The gene discussed is IL13RA2; the disease is glioma.